754230-78-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-5-bromo-3-benzloxypyridine is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and properties make it a key component in the development of new medications.
Used as an Antipyretic, Analgesic, and Anti-inflammatory Agent:
In the medical field, 2-Amino-5-bromo-3-benzloxypyridine is utilized for its potential to reduce fever, alleviate pain, and decrease inflammation. Its multifaceted therapeutic effects contribute to its value in treating a range of conditions.
Used in Corrosion Inhibition:
2-Amino-5-bromo-3-benzloxypyridine also has potential applications as a corrosion inhibitor, protecting materials from degradation and extending their lifespan in various industrial settings.
Used as a Building Block in Synthesis:
This chemical serves as a building block in the synthesis of a variety of biologically active compounds, contributing to the advancement of research and development in the chemical and pharmaceutical industries.
Overall, 2-Amino-5-bromo-3-benzloxypyridine's diverse properties and potential uses make it a promising compound for both research and industrial applications, with significant implications in medicine, material protection, and the creation of novel biologically active substances.

InChI:InChI=1/C12H11BrN2O/c13-10-6-11(12(14)15-7-10)16-8-9-4-2-1-3-5-9/h1-7H,8H2,(H2,14,15)

Upstream product

• 24016-03-3 2-amino-3-benzyloxypyridine 
• 144-55-8 sodium hydrogencarbonate 
• 100-39-0 benzyl bromide 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 39903-01-0 2-amino-3-hydroxy-5-bromopyridine 
• 100-44-7 benzyl chloride 

Downstream Products

• 362525-67-5 8-benzyloxy-6-bromo-2,3-dimethylimidazo[1,2-a]pyridine 
• 756520-51-1 4-(6-amino-5-benzyloxy-pyridin-3-yl)-benzoic acid methyl ester 
• 877619-67-5 4-(6-amino-5-benzyloxy-pyridin-3-yl)-benzoic acid 
• 1286716-32-2 ethyl 6-bromo-2-(chloromethyl)-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-33-3 ethyl 6-bromo-8-hydroxy-2-((phenylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-36-6 ethyl 6-bromo-2-((4-fluorophenylthio)methyl)-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-34-4 ethyl 6-bromo-2-((4-chlorophenylthio)methyl)-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-37-7 ethyl 6-bromo-2-((4-bromophenylthio)methyl)-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-35-5 ethyl 6-bromo-8-hydroxy-2-((p-tolylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-38-8 ethyl 6-bromo-8-hydroxy-2-((3-methoxyphenylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-10-6 ethyl 6-bromo-8-hydroxy-2-((phenylthio)methyl)-7-(pyrrolidin-1-ylmethyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-12-8 ethyl 6-bromo-8-hydroxy-2-((phenylthio)methyl)-7-(piperidin-1-ylmethyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-13-9 ethyl 6-bromo-8-hydroxy-7-((4-methylpiperazin-1-yl)methyl)-2-((phenylthio)methyl)imidazo[1,2-a]pyridine-3-carboxylate 
• 1286716-15-1 ethyl 6-bromo-7-((dimethylamino)methyl)-2-((4-fluorophenylthio)methyl)-8-hydroxyimidazo[1,2-a]pyridine-3-carboxylate 

Relevant academic research and scientific papers

Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome

A novel series of guanidinebenzoate enteropeptidase and trypsin dual inhibitors has been discovered and SAR studies were conducted. Optimization was focused on improving properties for gut restriction, including increased aqueous solubility, lower cellular permeability, and reduced oral bioavailability. Lead compounds were identified with efficacy in a mouse fecal protein excretion study.

5,8-DISUBSTITUTED-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL AND 5,8-DISUBSTITUTED-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF ENTEROPEPTIDASE

The present invention is directed to 5,8-disubstituted-[1,2,4]triazolo[1,5- a]pyridinyl and 5,8-disubstituted-imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the enteropeptidase enzyme.

CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

IMIDAZO[1,2-A]PYRIDINES AS SOLUBLE GUANYLATE CYCLASE STIMULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

IMIDAZO[1,2-A]PYRIDINES AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING CARDIOVASCULAR DISEASES

The present application relates to novel heterocyclyl- and heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE

The present application relates to novel 3-aryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

ARYL- AND HETARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDES AND USE THEREOF

The present application relates to novel aryl- and hetaryl-substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.